Prognostic Impact of HER2 Low Status in Male Breast Cancer: Prospective Cohort Analysis.

Background: Male breast cancer (MBC) is a rare disease, and the potential influence of low expression of human epidermal growth factor receptor 2 (HER2 low) remains unexplored.

Methods: In this prospective cohort study, we evaluated 870 patients treated for MBC between May 2009 and June 2023 to assess HER2 low status and its prognostic implications.

Results: With a median follow-up of 43 months (range 1-175 months), 659 eligible patients were categorized into three groups based on HER2 status: 501 (76%) HER2 low, 81 (12.

Tumor characteristics, therapy, and prognosis in young breast cancer patients ≤ 35 years.

Purposes: Young breast cancer patients aged 35 years and younger are a small group of women who tend to present at high-risk form of the disease. More analysis of the data on tumor characteristics, treatment, and survival is necessary to help improving treatment and outcome.

Methods: In this retrospective study, we compared the clinical and tumor characteristics, the treatments, and the survival of 257 women aged ≤ 35 years, with 6566 women aged 50-69 years.

Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer.

Objective: The aim of this study was to investigate the impact of pre-operative conization on disease-free survival (DFS) in early-stage cervical cancer.

Methods: In this population-based cohort study we analysed from clinical cancer registries to determine DFS of women with International Federation of Gynecology and Obstetrics (FIGO) stage IA1-IB1 cervical cancer with respect to conization preceding radical hysterectomy performed between January 2010 and December 2015.

Results: Out of 993 datasets available for the analysis, 235 patients met the inclusion criteria of the current study.

Survival Advantage of Lymphadenectomy in Patients with Ovarian Cancer.

We investigated the survival effect of lymphadenectomy in ovarian cancer. The five-year progression-free and overall survival in early-stage ovarian cancer were not affected. Preliminary, unadjusted analysis in advanced ovarian cancer suggested an improvement in survival.

The impact of G protein-coupled oestrogen receptor 1 on male breast cancer: a retrospective analysis.

Introduction: The G protein-coupled oestrogen receptor 1 (GPER-1) is a potential prognostic marker in breast cancer. However, its role in male breast cancer (MBC) is still unknown. This study evaluates the expression of GPER-1 in MBC samples and correlates these data with clinical and pathological parameters including patients' survival.

Contralateral lymph node metastases in patients with vulvar cancer and unilateral sentinel lymph node metastases.

Introduction: The risk of contralateral lymph node metastases following unilateral sentinel lymph node (SLN) metastases in patients with vulvar cancer(s) remains to be systematically assessed.

Material And Methods: We performed a multicenter, retrospective registry-based study of 476 patients with vulvar cancer. The primary outcome measure was the rate of contralateral non-SLN metastases in the case of positive unilateral SLN.

Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.

Background: The axillary lymph node status is one of the most important prognostic factors in patients with early breast cancer. However, the impact of axillary lymph node micrometastases on survival remains unclear. There are no consistent recommendations for adjuvant chemotherapy (CHT).

Minimal-invasive or open approach for surgery of early cervical cancer: the treatment center matters.

Purpose: The aim of the study was to compare recurrence-free survival (RFS) and overall survival (OS) of patients with early stage cervical cancer in dependence of surgical approach and treatment center.

Patients And Methods: A population-based cohort study including women with early stage IA1-IIB2 cervical cancer treated by radical hysterectomy between January 2010 and December 2015 was performed.

Results: The median follow-up time was 5.

Comparison of survival of patients with endometrial cancer undergoing sentinel node biopsy alone or systematic lymphadenectomy.

Background: Recently, sentinel lymph node mapping was introduced in the surgical staging of endometrial cancer as alternative to systematic lymphadenectomy. However, the survival impact of sentinel node mapping is not well characterized yet.

Methods: We performed retrospective study of 104 patients with endometrial cancer treated with sentinel lymph node alone (n = 52) or with pelvic and para-aortic lymphadenectomy (n = 52).

Systematic lymphadenectomy in early stage endometrial cancer.

Background: The positive effect of systematic lymphadenectomy on survival of patients with endometrial cancer is a topic of ongoing debate.

Methods: We aimed to investigate whether systemic lymphadenectomy is beneficial for patients with early endometrial cancer. For this purpose, we analyzed a population-based registry with of 2392 women with endometrioid endometrial cancer, stage I and II at intermediate and high risk of recurrence.

Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis.

Background: Due to the lack of prospective data, current treatment of male breast cancer (MBC) is based on information obtained from retrospective analysis or by extrapolation from studies on female patients. In this prospectively enrolled cohort study, we retrospectively examined the survival effect of tamoxifen in MBC patients.

Methods: In this prospectively enrolled cohort study, 448 patients with MBC were treated between May 2009 and June 2018.

Lymph node micrometastases and outcome of endometrial cancer.

Background: The relationship between nodal micrometastases and clinical outcome of endometrial cancer is unclear.

Patients And Methods: We performed a multicenter, retrospective registry-based study of 2392 patients with endometrial cancer with and without nodal micrometastases. The primary outcome measure was disease-free survival.

Loss of HER2 after HER2-targeted treatment.

Purpose: HER2 expression has been reported to be discordant between primary tumor and metastatic tissue.

Patients And Methods: HER2 discordance and relation to HER2-targeted treatment was investigated in 227 patients with primary breast cancer.

Results: HER2 discordance between primary biopsy and second biopsy after neoadjuvant or adjuvant treatment was observed in 20.

Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.

Purpose: Thromboembolism is a common adverse event in women treated with tamoxifen (TAM) for breast cancer. The risk in male breast cancer patients is poorly investigated. We aimed to examine the risk of thrombotic events after TAM in male breast cancer patients.

Endometrial cancer subtypes are associated with different patterns of recurrence.

Purpose: To evaluate the pattern of endometrial cancer recurrence according to its biological subtype in a large cohort of patients.

Patients And Methods: Patients were stage eligible if they had a description of registry risk of recurrence status and were not primary metastatic. Data were prospectively collected.

Vaginal brachytherapy for endometrial cancer.

Background: There is limited information about survival effect of vaginal brachytherapy (VBT) and its comparison to external beam pelvic radiotherapy (EBRT) and no radiotherapy (no-RT) of endometrial cancer patients.

Patients And Methods: We performed a multicenter retrospective registry study of 1550 patients with endometrial cancer treated by no-RT (n = 702), VBT (n = 430) and EBRT ± VBT (n = 418). The outcome measure was overall survival.

Patterns of breast cancer relapse in accordance to biological subtype.

Purpose: To evaluate the pattern of recurrence of breast cancer according to its biological subtype in a large cohort of patients treated with therapy representative of current practice.

Patients And Methods: Patients treated between 2000 and 2016 with known biological subtype were eligible. Data were prospectively collected.

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).

Purpose The GeparQuinto phase III trial demonstrated a lower pathologic complete response (pCR; pT0 ypN0) rate when lapatinib was added to standard anthracycline-taxane chemotherapy compared with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer. Here, we report the long-term outcomes. Methods Patients with HER2-positive tumors (n = 615) received neoadjuvant treatment with epirubicin (E) plus cyclophosphamide (C), followed by docetaxel (T) in combination with either lapatinib (L) or trastuzumab (H; ECH-TH arm: n = 307; ECL-TL arm: n = 308).

Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival.

Background: Oophorectomy is generally performed in patients with endometrial cancer despite the rate of ovarian metastasis being relatively low.

Patients And Methods: A multicenter retrospective registry-based study was performed in 2329 patients with endometrial cancer. The outcome measures were the incidence of ovarian metastasis and the impact on overall survival.

Management of elderly women with cervical cancer.

Background: Elderly women with cervical cancer receive less therapy in comparison with their younger counterparts. The exact reason(s) for this treatment strategy remains unclear.

Patients And Methods: We performed a multicenter, retrospective registry-based study of 1559 patients with cervical cancer.

A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study.

Purpose: Precise presurgical diagnosis of tumour size is essential for adequate treatment of male breast cancer (MBC). This study is aimed to compare the accuracy of clinical measurement (CE), ultrasound (US) and mammography (MG) for preoperative estimation of tumour size.

Methods: This study was conducted as a prospective, multicentre register study.

Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.

Background: Our goal was to compare the survival advantage of tamoxifen (TAM) and aromatase inhibitor (AI) in female (FBC) and male breast cancer (MBC).

Patients And Methods: We performed a retrospective study of 2785 FBC and 257 MBC patients treated with hormonal therapy.

Results: The median follow-up was 106 months (range 3-151 months) and 42 months (range 2-115 months) for FBC and MBC, respectively.

Management of elderly women with endometrial cancer.

Background: Elderly women with endometrial cancer receive less therapy in comparison with their younger counterparts. The exact reason(s) for this treatment strategy remains unclear.

Patients And Methods: We performed a multicenter, retrospective registry-based study of 1550 patients with endometrial cancer.

Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer.

Background: External beam radiation therapy (EBRT) with concomitant chemotherapy (cCT) (=RCT) plus intracavitary (±interstitial) brachytherapy (iBT) is standard of care for advanced cervical cancer. The aim of this study was to evaluate morbidity and survival outcome of simple adjuvant hysterectomy (AH) after EBRT/cCT and to compare it with the standard treatment.

Patients And Methods: Patients with FIGO stage III cervical cancer were treated with EBRT/cCT and then divided in two groups: group 1 was further treated with standard intracavitary/interstitial BT, while group 2 underwent AH.